Q-omics provides the consensus-scored MIF4GD profile across patient tissues and cancer cell-line models. MIF4GD expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIF4GD is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, MIF4GD protein abundance shows 18,345 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UCEC, and KICH as cancer lineages where MIF4GD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIF4GD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIF4GD survival associations across molecular data types. MIF4GD RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIF4GD RNA expression–survival associations across cancer types. High MIF4GD expression shows unfavorable associations in LIHC, but favorable associations in UCEC, BRCA, KIRC, SARC and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for MIF4GD RNA expression.
This table summarizes MIF4GD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MIF4GD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIF4GD shows lower tumor expression in KICH and higher tumor expression in KIRP, COAD, LIHC, THCA and BRCA. The KICH box plot shows higher MIF4GD RNA expression in normal versus tumor tissue (log2 FC = −1.367, t-test p < 0.001).
This table shows molecular features associated with MIF4GD in patient tissues and cancer cell lines. In patient samples, MIF4GD shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, MIF4GD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
